Form 4: ImmunityBio Director Sells Shares After Option Exercise

ImmunityBio Director Christobel Selecky exercised stock options and immediately sold 25,000 shares of common stock for a profit.

Summary

• Christobel Selecky, a Director of ImmunityBio, Inc. (IBRX), reported transactions on February 23, 2026.
• Exercised stock options to acquire 25,000 shares of common stock at an exercise price of $2.98 per share.
• Concurrently sold 25,000 shares of common stock at a price of $10.00 per share.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on June 12, 2025.
• Following these transactions, the reporting person directly owns 0 shares of common stock.
• The reporting person still beneficially owns 67,937 stock options.
• The exercised options vested on June 12, 2023, and have an expiration date of June 14, 2032.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a routine insider transaction under a pre-arranged plan, where a director realized value from vested options. While a sale, it's not necessarily a negative signal given the 10b5-1 plan.

Positives

• Director Selecky realized a significant profit from the option exercise and sale, indicating a substantial gain from her equity compensation.
• The sale price of $10.00 per share is considerably higher than the exercise price of $2.98 per share, reflecting a positive valuation for the shares sold.

Negatives

• A director selling shares, even under a pre-arranged plan, can sometimes be perceived negatively by the market as it reduces their direct equity stake in the company.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

StockSavvy.ai notes that insider transactions, particularly sales by directors, are closely watched by investors for signals about management's confidence in the company's future prospects. While sales under a Rule 10b5-1 plan are pre-scheduled and often less indicative of immediate sentiment, the realized profit highlights the value of equity compensation in the biotech sector.

Stakeholder Impact

• Shareholders: The sale by a director, even if planned, might be interpreted differently by various shareholders. Those looking for strong insider buying might see it as a slight negative, while others might view it as a normal part of executive compensation.

Key Dates

Recommendation

The filing details a pre-scheduled insider transaction where a director exercised options and sold shares for a profit. This is a routine event and does not provide new fundamental information about the company's operations or future prospects that would warrant a change in investment recommendation. Investors should hold and monitor future company performance and broader market trends.

Keywords

ImmunityBio, IBRX, Form 4, Insider Trading, Stock Option Exercise, Share Sale, Director Transaction, Christobel Selecky, Rule 10b5-1